Factors independently associated with ICH
| Effect . | χ2 . | HR (95% CI) . |
|---|---|---|
| Region | 47.41 | |
| Asia vs Europe | 3.19 (2.18-4.68) | |
| Latin America vs Europe | 1.57 (1.02-2.43) | |
| North America vs Europe | 0.91 (0.57-1.44) | |
| Randomized treatment (apixaban vs warfarin) | 27.97 | 0.42 (0.30-0.58) |
| Age (5-y increase) | 25.54 | 1.25 (1.15-1.36) |
| Prior stroke/TIA | 13.47 | 1.83 (1.33-2.52) |
| Aspirin at randomization | 3.97 | 1.37 (1.01-1.86) |
| Effect . | χ2 . | HR (95% CI) . |
|---|---|---|
| Region | 47.41 | |
| Asia vs Europe | 3.19 (2.18-4.68) | |
| Latin America vs Europe | 1.57 (1.02-2.43) | |
| North America vs Europe | 0.91 (0.57-1.44) | |
| Randomized treatment (apixaban vs warfarin) | 27.97 | 0.42 (0.30-0.58) |
| Age (5-y increase) | 25.54 | 1.25 (1.15-1.36) |
| Prior stroke/TIA | 13.47 | 1.83 (1.33-2.52) |
| Aspirin at randomization | 3.97 | 1.37 (1.01-1.86) |
c-index: 0.733. c-index by region: North America: 0.713, Latin America: 0.655, Europe: 0.667, Asia: 0.742. Other variables considered for inclusion: race, sex, weight, history of bleeding, history of anemia, history of falls within a year, coronary artery disease, hypertension, alcohol use at randomization, liver disease, creatinine clearance, hemoglobin, prior vitamin K antagonist use, and nonsteroidal anti-inflammatory drugs at randomization.